Protalix Biotherapeutics Inc
AMEX: PLX · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Protalix Biotherapeutics Inc (PLX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-5.09M | $-10.45M | $-16.02M | $44.45M | $-38.46M | $-23.57M | $635000.00 | $-30.65M | $-29.28M | $-24.28M | $-32.10M | $-9.99M | $-7.74M | $-19.36M | $-26.11M | $-10.29M | $-25.00M | $-1.32M | $8.67M | $-11.99M |
| Capital expenditures | $842000.00 | $2.33M | $3.37M | $6.20M | $7.86M | $5.71M | $2.07M | $1.89M | $785000.00 | $464000.00 | $849000.00 | $971000.00 | $686000.00 | $627000.00 | $655000.00 | $1.46M | $628000.00 | $1.15M | $1.28M | $1.64M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $3.42M | $10.85M | $3.07M | $2.68M | $1.28M | $886000.00 | $7.75M | $4.09M | $1.24M | $1.80M | $988000.00 | $337000.00 | $514000.00 | $835000.00 | $3.13M | $2.38M | $2.08M | $3.45M | $3.25M | $2.30M |
| Free cash flow | $-5.93M | $-12.78M | $-19.39M | $38.26M | $-46.32M | $-29.27M | $-1.43M | $-32.54M | $-30.07M | $-24.75M | $-32.95M | $-10.96M | $-8.43M | $-19.98M | $-26.76M | $-11.74M | $-25.63M | $-2.47M | $7.39M | $-13.63M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | $-15.05M | $18.38M | $-26.66M | $-29.43M | $21.61M | $-13.09M | $-12.12M | $498000.00 | $835000.00 | — | — | — | — | — | — |
Frequently asked questions
What is Protalix Biotherapeutics Inc's revenue?
Protalix Biotherapeutics Inc's trailing twelve-month revenue is $76.38M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is PLX?
In its most recent fiscal year, PLX ran a gross margin of 47.85%, an operating margin of -10.43%, and a net margin of -12.52%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does PLX generate?
PLX produced $-13.63M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is PLX's balance sheet healthy?
PLX holds $14.68M in cash and equivalents against — in long-term debt, on $48.23M of shareholder equity. That debt is best read against the cash flow the business throws off each year.